Hyperactivating JAK2 mutations are the key drivers of myeloproliferative neoplasms (MPNs), a group of diseases characterized by abnormal proliferation of hematopoietic progenitor cells in the bone marrow. This evidence concerns the gene JAK2 and myeloproliferative disorder.